LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia

The purpose of this study is to obtain high quality specimens for molecular studies for the identification and characterization of genetic mutations involved in the pathogenesis of familial myeloid ma...

Lead sponsor: Wake Forest University Health Sciences•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

TERMINATEDPhase 2

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

NCT01106950 · Leukemia, Myelogenous, Acute

TERMINATEDPhase 1

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

NCT01085656 · Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 21, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment6

Start dateNov 2013

Last updatedApr 21, 2022

Condition

Leukemia, Myelogenous, Acute

Locations shown

Levine Cancer Institute

Charlotte, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2022Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions